Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial

Supportive Care in Cancer

Volumn 23, Issue 11, 2015, Pages 3229-3237

  Bakhshi, Sameer ^a   Batra, Atul ^a   Biswas, Bivas ^a   Dhawan, Deepa ^a   Paul, Reeja ^a   Sreenivas, Vishnubhatla ^b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti emetics; Aprepitant; Pediatric cancer

Indexed keywords

APREPITANT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ONDANSETRON; VINBLASTINE; VINCRISTINE; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ADD ON THERAPY; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; FEMALE; FEVER; FLUID INTAKE; FOOD INTAKE; GASTRITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; INDUCTION CHEMOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEOPLASMS; ONTARIO; PRESCHOOL CHILD; REMISSION; VOMITING;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIEMETICS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MORPHOLINES; NAUSEA; NEOPLASMS; NEUROKININ-1 RECEPTOR ANTAGONISTS; ONDANSETRON; ONTARIO; REMISSION INDUCTION; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84942502117     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2714-9     Document Type: Article

References (25)

1. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494
2. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol Off J Am Soc Clin Oncol 17(9):2971–2994
3. Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S et al (2012) Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol 19(6):e414–e421
4. Grunberg SM, Slusher B, Rugo HS (2003) Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 11(2 Suppl 1):1–18, quiz 2 p following 18
5. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 15(5):497–503
6. Richardson JL, Marks G, Levine A (1988) The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 6(11):1746–1752
7. Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB et al (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 12(3 Suppl 4):32–37
8. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, de Wit R et al (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer Oxf Engl 1990 41(9):1278–1285
9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis—antiemesis.pdf [Internet]. [cited 2014 Jan 1]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
10. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol Off J Eur Soc Med Oncol ESMO 21(Suppl 5):v232–v243
11. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 29(31):4189–4198
12. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52(2):242–247
13. Bodge M, Shillingburg A, Paul S, Biondo L (2013) Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study. Pediatr Blood Cancer
14. Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C et al (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60(7):1073–1082
15. Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P et al (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57(2):191–198
16. Pillai AK, Sharma KK, Gupta YK, Bakhshi S (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 56(2):234–238
17. Nausea and Vomiting (PDQ®)—National Cancer Institute [Internet]. [cited 2014 Jan 1]. Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page1/AllPages
18. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098
19. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol Off J Am Soc Clin Oncol 21(22):4112–4119
20. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104(4):864–868
21. Choi MR, Jiles C, Seibel NL (2010) Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol 32(7):e268–e271
22. Shillingburg A, Biondo L (2014) Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther JPPT Off J PPAG 19(2):127–131
23. Duggin K, Tickle K, Norman G, Yang J, Wang C, Cross SJ et al (2014) Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors. J Pediatr Oncol Nurs Off J Assoc Pediatr Oncol Nurses 31(5):277–283
24. Bauters TGM, Verlooy J, Robays H, Benoit Y, Laureys G (2013) Emesis control by aprepitant in children and adolescents with chemotherapy. Int J Clin Pharm 35(6):1021–1024
25. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104(17):1280–1292